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Abstract. Psoriasin, a member of the S100 multigenic family, 
which is aberrantly expressed in a variety of human tumors, 
is considered as an attractive molecular target for cancer 
treatment. The present study aimed to characterize the role 
of psoriasin in gastric cancer (GC), the associated pathways 
through which it contributes to cancer development and 
progression, and the effect of psoriasin on cellular response to 
pre-operative chemotherapy in patients with GC. Expression 
of psoriasin mRNA and protein were analyzed using quantita-
tive polymerase chain reaction and immunohistochemistry of 
gastric cancer cohorts, respectively. Gastric cancer cell models 
with differential expression of psoriasin were generated using 
stable cell lines that overexpressed psoriasin. The in vitro 
biological functions of the cells in response to psoriasin 
overexpression and to chemotherapeutic agents were assessed 
using various cell-based assays. Psoriasin was overexpressed 
in patients with advanced GC, and high psoriasin levels led 
to poor clinical outcomes. Increasing psoriasin expression 
in GC cell lines promoted cell proliferation, migration and 
invasion in vitro. Furthermore, psoriasin overexpression 
caused alterations in the levels of epithelial-mesenchymal 
transition-associated proteins, and activated the extracellular 
signal-regulated kinase signaling pathway. Additionally, higher 
levels of psoriasin expression were significantly associated a 
lack of response to neoadjuvant chemotherapy in patients with 
GC. Psoriasin overexpression tended to decrease the sensitivity 
of GC cells to cisplatin, potentially by inhibiting apoptosis 
or increasing the S-phase population. Taken together, these 
results indicate that psoriasin may be a promising therapeutic 
target for GC treatment, and a potential molecular marker to 
predict patient response to pre-operative chemotherapy.
Introduction
Gastric cancer (GC) currently ranks as the fourth most frequently 
diagnosed cancer and the second leading cause of mortality from 
malignant diseases worldwide (1). According to statistics, >950 
000 new GC cases are diagnosed every year, and an estimated 
723,100 mortalities occurred in 2012 (1,2). By the time of diag-
nosis, the majority of patients present with advanced GC, with a 
5-year survival rate of <30% (3,4). Pre-operative chemotherapy 
has been successfully used in the treatment of locally advanced 
GC, as it may increase the possibility of complete resection 
through shrinking the tumor (5). Based on clinical data, patients 
with GC that exhibit a positive response to neo-adjuvant chemo-
therapy can obtain a better prognosis than non-responders (5). 
However, different patients exhibit distinct therapeutic responses 
due to various genetic and epigenetic alterations that are involved 
in gastric tumorigenesis (4,6). Therefore, a comprehensive under-
standing of the molecular variables that affect the GC disease 
pathway may contribute to identifying novel therapeutic targets 
or prognostic biomarkers that may help identify patients that are 
likely to benefit from chemotherapy.
Psoriasin, also termed S100A7, belongs to the S100 multi-
genic family of calcium-binding EF-hand proteins and was 
initially identified in 1991 as a highly expressed protein in 
psoriatic keratinocytes (7,8). Psoriasin, a low molecular weight 
protein (11.4 kDa), is localized in the cytoplasm, cell nucleus or 
secreted outside of the cell in certain cases (9,10). Dysregulated 
expression of psoriasin has been observed in various types of 
cancer, including oral squamous cell carcinoma (11), breast 
cancer (10,12), lung cancer (13), bladder cancer (14), skin 
cancer (15), head and neck cancer (16), prostate cancer (17) and 
cervical cancer (18). Functionally, psoriasin usually has malig-
nant functions in cancer; however, it can also exhibit tumor 
suppressive effects in certain types of oral carcinoma and breast 
cancer by decreasing β-catenin activity (11,12). Subsequent 
studies have suggested that intracellular and secreted forms of 
psoriasin protein have an important role in tumor development 
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by regulating cell proliferation, metastasis, migration, invasion, 
apoptosis and angiogenesis (17-19). Mechanistically, several 
signaling pathways have been demonstrated to have a corre-
lation with psoriasin, including Hippo, receptor for advanced 
glycation endproducts (RAGE), extracellular signal-regulated 
kinase (ERK), β-catenin and nuclear factor (NF)-κB pathways. 
The downregulation of psoriasin in lung cancer suppresses cell 
growth and invasive potential by regulating NF-κB activity and 
the expression of matrix metalloproteinases and vascular endo-
thelial growth factor (19). Similarly, psoriasin promotes cell 
survival by binding to c-Jun activation domain-binding protein1 
and enhancing the phosphorylation of NF-κB and protein 
kinase B in breast cancer (20). Another study demonstrated 
that psoriasin binds to RAGE and activates ERK signaling to 
increase migration and invasion in cervical cancer (18).
However, the role of psoriasin in GC and its underlying 
mechanisms remain unclear. To the best of our knowledge, 
the present study is the first to characterize the expression 
of psoriasin in patients with GC and investigate the role of 
psoriasin in GC pathogenesis. Psoriasin was markedly upregu-
lated in patients with GC and high expression of psoriasin was 
associated with poor survival. Furthermore, psoriasin posi-
tively regulated ERK signaling and promoted proliferation, 
migration and invasion. In addition, overexpression of psori-
asin decreased the sensitivity of GC cells to cisplatin. Taken 
together, the findings suggested that psoriasin has a critical 
role in the pathogenesis of GC and may be a novel therapeutic 
target or a potential diagnostic marker for the patient response 
to pre-operative chemotherapy in GC.
Materials and methods
Cell line and cell culture. The human AGS (no. 89090402) and 
HGC-27 (no. 94042256) GC cell lines were purchased from 
the European Collection of Animal Cell Cultures (ECACC; 
Salisbury, UK). The cells were cultured in Dulbecco's modi-
fied Eagle's medium (DMEM)-F12 medium (Sigma-Aldrich; 
Merck KGaA, Darmstadt, Germany), supplemented with 
10% fetal calf serum (FCS; Sigma-Aldrich; Merck KGaA) and 
1% antibiotics (penicillin and streptomycin; Sigma-Aldrich; 
Merck KGaA) at 37˚C in a humidified 5% CO2 atmosphere.
Patients and human GC tissue. Two cohorts were used in the 
present study, namely a generic collection and a collection with 
chemosensitive information. The first cohort had a total of 321 GC 
tissues and 173 adjacent normal tissues were collected from 
patients with GC that underwent surgical resection, and some 
were treated with preoperative radiotherapy or chemotherapy at 
the Peking University Cancer Hospital (Beijing, China). Tissue 
and data were obtained between September 2003 and December 
2007. The mean age of the patients in the cohort was 59.8 years 
with male/female ratio of 229:92 (Table I). The other cohort 
comprised of 87 patients with GC that had received chemotherapy 
with oxaliplatin/5-fluorouracil/leucovorin prior to surgery at the 
Peking University Cancer Hospital between December 2001 
and November 2006. All of the tissues were stored immedi-
ately following surgery at -80˚C until use. Clinicopathological 
and follow-up information was obtained from patient data. GC 
staging was determined according to the 2010 tumor-node-
metastasis (TNM) classification recommended by the American 
Joint Committee on Cancer (AJCC 7th edition) (21). This study 
was approved by Peking University Cancer Hospital Research 
Ethics Committee (ethics no. 2006021) and written consent was 
obtained from all patients involved.
RNA isolation, reverse transcription, conventional poly-
merase chain reaction (PCR) and quantitative PCR (qPCR). 
Total RNA was extracted from cells or homogenized tissues 
using TRI reagent (Sigma-Aldrich; Merck KGaA) following 
the manufacturer's instructions, and subsequently reverse 
transcribed into cDNA using Promega Reverse Transcription 
kit (Promega Corporation, Madison, WI, USA). The reverse 
transcription conditions were annealing at 25˚C for 5 min, 
extension at 42˚C for 60 min, and inactivation at 70˚C for 15. 
PCR was then performed using GoTaq Green MasterMix 
(Promega Corporation) under the cycling conditions as follows: 
Table I. Association between psoriasin mRNA expression and 
clinicopathological features in gastric cancer tissues.
Variable n Psoriasin P-value
  expression
  (median)
Tissue   <0.001
  Tumor 321   12.00
  Adjacent normal 173     0.04
Sex     0.573
  Male 229     9.00
  Female   92   13.00
Depth of invasion     0.011
  T1-2   42     1.00
  T3-4 279   15.00
Lymph node status   <0.001
  N0   71     0.03
  N1+2+3 250   16.00
Distant metastasis   <0.001
  M0 280     4.00
  M1   41 384.00
TNM staging   <0.001
  I+II   85     1.00
  III+IV 236   17.00
Differentiation
  High     1     0.15
  High-medium   21   20.00
  Medium   67   15.00   0.629a
  Medium-low   87   13.00   0.732a
  Low 145     3.00   0.453a
Clinical outcome   <0.001
  Alive 134     1.00
  Died 187   25.00
aCompared with high-medium differentiation; Mann-Whitney U test 
for comparisons between two groups; Kruskal-Wallis test for multiple 
group followed Tukey honest significant difference as post hoc test. 
TNM, tumor-node-metastasis.
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95˚C for 2 min, followed by 40 cycles of 95˚C for 30 sec, 55˚C 
for 30 sec and 72˚C for 30 sec, and a final extension of 5 min 
at 72˚C. The PCR products were visualized on 1-2% agarose 
gels stained with SYBR Safe (Invitrogen; Thermo Fisher 
Scientific, Inc., Waltham, MA, USA). The primer sequences 
used for PCR in this study are listed in Table II.
qPCR was run on the StepOne Plus Real-Time PCR system 
(Applied Biosystems; Thermo Fisher Scientific, Inc.), using 
Precision FAST 2X qPCR MasterMix (Primerdesign Ltd., 
Chandler's Ford, UK) in a final volume of 10 µl. cDNA samples 
from GC cells and two cohorts of GC tissues were examined 
for psoriasin transcript expression with standard and negative 
controls. Reaction conditions were as follows: 94˚C for 10 min, 
followed by 100 cycles of 94˚C for 10 sec, 55˚C for 30 sec and 72˚C 
for 10 sec. GAPDH or actin was used as an internal control. The 
primer sequences used for qPCR are listed in Table II. Primers 
for qPCR were designed to the specific target using the Beacon 
Designer software (version 2; Premier Biosoft International, 
Palo Alto, CA, USA). An additional sequence, known as the Z 
sequence (5'-ACTGAACCTGACCGTACA-3'), which acts as a 
template for the amplifluor uniprimer probe, was added with the 
reverse primers. Expression of the target sequence was qualified 
in conjunction with a range of known dilution series of podo-
planin gene transcript, which are used to generate a standard 
curve to enable the calculation of transcript copy.
Construction of psoriasin overexpression vector in GC cell 
lines. Full-length human psoriasin coding sequence was 
amplified from human prostate tissues with appropriate 
primers (Table I). The synthesized product was cloned into the 
pEF6/V5-His-TOPO plasmid vector (K961020; Invitrogen; 
Thermo Fisher Scientific, Inc.) according to the manufac-
turer's instructions. The overexpression constructs and control 
plasmids (25 µg pre transfection) were then transfected into 
2.5x106 AGS and HGC-27 cells using a Gene Pulser Xcell 
electroporation system (Bio-Rad Laboratories, Inc., Hercules, 
CA, USA). After 2 weeks of selection using 6 µg/ml blasticidin 
(Melford Laboratories, Ltd., Ipswich, UK), stable transfectants 
were obtained and verified for psoriasin overexpression. Then 
cells were cultured in DMEM with a lower concentration of 
blasticidin (0.6 µg/ml) to maintain plasmid expression.
Treatment with ERK inhibitor and cisplatin. AGS and HGC-27 
were cultured in serum-free medium for 4-6 h, and then treated 
with 1 µM ERK inhibitor (FR 180204; Tocris Bioscience, 
Bristol, UK) or 16.6 µM cisplatin (Tocris Bioscience) for 24 h, 
followed by PCR, western blotting or flow cytometry analysis.
Western blotting. AGS and HGC-27 were isolated by pre-chilled 
lysis buffer (50 mM Tris-Cl, pH 7.5, 1% Nonidet P-40, 0.5% 
sodium deoxycholate, 0.05% SDS, 1 mM EDTA, 150 mM 
NaCl) containing protease inhibitor cocktail (aprotinin and 
leupeptin) and phosphorylation inhibitor (sodium vanadate) and 
qualified with a DCTM protein assay kit (Bio-Rad Laboratories, 
Inc.). Protein extract of each sample (30 µg) was separated 
by 10% or 12% SDS-PAGE and transferred onto a 0.45 µm 
Table II. Primers sequences.
Name Forward Reverse
Psoriasin  ATGAGCAACACTCAAGCTG ACTGGCTGCCCCCGGAACA
Psoriasin (qPCR) TGTGACAAAAAGGGCACAAA ACTGAACCTGACCGTACACCCAGCAAGGACAGAAACTC
Snail CGCTCTTTCCTCGTCAG GTTGCAGTATTTGCAGTTGA
Slug CTCTCCTCTTTCCGGATACT AGCAGTTTTTGCACTGGTAT
Vimentin GATGCTTCAGAGAGAGGAAG CTCTTCGTGGAGTTTCTTCA
E-cadherin CGAGAGCTACACGTTCAC GGGAAAAATAGGCTGTCCTT
N-cadherin CAACGACGGGTTAGTCAC ATTGGGGTCTGGAGTTTC
Zeb-1 CTTGTGATTTGTGTGACAAGA ATGCCTTTTTACAGATTCCA
MMP-2 TTTGATGACGATGAGCTATG TGCAGCTCTCATATTTGTTG
MMP-3 TCATTTTGGCCATCTCTTCC GTGCCCATATTGTGCCTTCT
MMP-9 AACTACGACCGGGACAAG ATTCACGTCGTCCTTATGC
ERK1 ACACGCAGTTGCAGTACA CCACATACTCCGTCAGGA
ERK2 CCAACCTCTCGTACATCG GTCAGGAACCCTGTGTGA
c-Fos CAGACTACGAGGCGTCATCC TCTGCGGGTGAGTGGTAGTA
c-Jun AAGATCCTGAAACAGAGCAT GCTGGACTGGATTATCAGG
Cyclin D1 CGGTGTCCTACTTCAAATGT ACCTCCTCCTCCTCCTCT
Cyclin D2 GGAGAAGCTGTCTCTGATCC GGGTACATGGCAAACTTAAA
GAPDH CGCTGCTTTTAACTCTGGTA GACTGTGGTCAGAGTCCTT
GAPDH (qPCR) CTGAGTACGTCGTCGTGGAGTC ACTGAACCTGACCGTACACAGAGATGATGACCCTTTTG
Actin (qPCR) GGACCTGACTGACTACCTCA ACTGAACCTGACCGTACAAGCTTCTCCTTAATGTCACG
The underlined sequence in the reverse primers is the additional Z sequence which is complementary to the universal Z probe. qPCR, 
quantitative polymerase chain reaction; Zeb-1, zinc finger E-box-binding homeobox 1; MMP, matrix metalloproteinase; ERK, extracellular 
signal-regulated kinase.
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polyvinylidenedifluoride membrane (EMD Millipore, Billerica, 
MA, USA). The membranes were blocked with 5% non-fat dried 
milk in PBST solution (0.05% Tween-20 in PBS) for 1 h at room 
temperature. The blocked membranes were then incubated in 
a diluted primary antibodies (1:500) overnight as 4˚C, washed 
in PBST and incubated with a diluted specific horseradish 
peroxidase (HRP)-conjugated secondary antibody (1:2,000) 
for 1 h at room temperature. The following primary antibodies 
were used in the study: Anti-S100A7/psoriasin (clone 47C1068; 
catalog no.; Novus Biologicals, Ltd., Cambridge, UK); phospho 
(p)-ERK (Tyr 204; cat. no. sc-7976), ERK1/2 (clone C-9; 
cat. no. sc-514302), p21 (cat. no. sc-6246), p53 (clone DO-1; 
cat. no. sc-126), vimentin (cat. no. sc-66002), E-cadherin 
(cat. no. sc-1500), N-cadherin (cat. no. sc-7939), zinc finger E-box 
binding homeobox 1 (Zeb-1; cat. no. sc-81428) and GAPDH 
(cat. no. sc-32233; all Santa Cruz Biotechnology, Inc., Dallas, 
TX, USA). The HRP secondary antibodies (cat. no. A5278, 
anti-mouse IgG; cat. no. A0545, anti-rabbit IgG) were obtained 
from Sigma-Aldrich (Merck, KGaA). Detection was performed 
using an EZ-ECL chemiluminescence kit (Biological Industries 
USA, Inc., Cromwell, CT, USA). Immunoreactive bands were 
visualized and quantified by densitometry using the Syngene 
G:BOX chemiluminescence imaging system and Gene Tools 
4.03 (Syngene Europe, Cambridge, UK).
Cell proliferation assay. Briefly, AGS and HGC-27 cells were 
seeded into 96-well plate (2x103 cells/well) in 6 replicates 
followed by incubation for 0, 1, 2, 3, 4 and 5 days. Following 
fixation in 4% formalin for 30 min at room temperature, the cells 
were stained with 0.5% (w/v) crystal violet (Sigma-Aldrich) 
for 15 min at room temperature. Following washing, the cells 
were then extracted with 10% (v/v) acetic acid and cell density 
was determined by measuring the absorbance at 540 nm 
using a spectrophotometer (Elx800; BioTek Instruments, Inc., 
Winooski, VT, USA).
Cell viability assay. To evaluate the cytotoxicity of cisplatin, AGS 
and HGC-27 cells were plated into 96-well plate (cells/well) in 6 
replicates. After 24-h incubation, the cells were exposed to serial 
concentrations of cisplatin (0, 3.125, 6.25, 12.5, 25 and 50 µM, 
respectively) for 72 h. Cells viability was assessed by staining 
with 0.5% (w/v) crystal violet for 15 min at room temperature.
Cell colony assay. AGS and HGC-27 were plated into 6-well 
plate at the density of 400 cells/ well and incubated at 37˚C 
and at an atmosphere of 5% CO2 for 2 weeks. The cell colo-
nies were fixed in 4% formalin for 30 min and stained with 
0.5% (w/v) crystal violet for 15 min. After images were taken 
with a camera, the colonies were dissolved in 10% (v/v) acetic 
acid, and the absorbance was measured at 540 nm using a 
spectrophotometer (Elx800; BioTek Instruments, Inc.).
Cell-matrix adhesion assay. A total of 2x104 cells were plated 
in each well of a black 96-well plate previously coated with 
Matrigel (10 µg/well; Corning Incorporated, Corning, NY, 
USA) in 6 replicates. After incubation for 1 h, the cells were 
washed once with PBS and then incubated in cell dissociation 
solution (100 µl/well; Sigma-Aldrich; Merck KGaA) for 30 min 
containing 0.002 µg/µl calcein AM (eBioscience; Thermo Fisher 
Scientific, Inc.). Fluorescence of the cell suspension was 
read using a GloMax®-Multi Detection System (Promega 
Corporation) at 495 nm for excitation and 519 nm for emission.
In vitro invasion assay. Cells (5x104) were loaded into an 
8 µm-pore ThinCertTM 24-well plate insert (Greiner Bio-One 
International GmbH, Kremsmünster, Austria) coated with 
100 µg Matrigel (each sample in triplicate). The upper chamber 
was provided with serum-free medium, and the lower chamber 
was filled with DMEM with 10% FCS. Following incubation 
for 24 h, the underside of the insert was incubated in 350 µl 
dissociation solution containing 1 µM calcein AM for 1 h. The 
cell suspension was then aliquoted into a black 96-well plate 
(100 µl/well) and read using the GloMax®-Multi Detection 
System at 495 nm for excitation and 519 nm for emission.
In vitro cell migration assay and the effect of ERK inhibitor 
on cell mobility. Electric cell-substrate impedance sensing 
(ECIS) instruments (Applied Biophysics, Inc., Troy, NY, USA) 
were used to monitor cell migration by detecting impedance 
variation based on the current flow change on the gold elec-
trodes of a 96-well array (Applied Biophysics Inc.) (22). There 
are two parameters, resistance and capacitance, derived from 
current and voltage measurements. Among them, resistance, 
consisting of para- and trans-cellular current flow, is better to 
represent the quality and function of cell barrier (23). Briefly, 
6x104 cells diluted in 200 µl DMEM with or without ERK 
inhibitor (1 µM) were seeded into each ECIS 96-plate well, and 
the cells were wounded by applying electric current (3,000 µA, 
60 kHz) when confluent monolayers were formed. The array 
was placed into a CO2 incubator, which was connected to 
the ECIS Model 9600 Controller, and the impedance data, 
which indicate cellular migration, were collected continuously 
for 6 h. In this study, the normalized resistance measured at 
4,000 Hz was chosen to evaluate cell function due to its high 
sensitivity to the current flow variation caused by the change 
of cell behavior as described in the literature (24).
Flow cytometric analysis. For protein expression analysis, 
AGS and HGC-27 were fixed with IC Fixation Buffer (eBiosci-
ence; Thermo Fisher Scientific, Inc.) at room temperature for 
30 min, and then permeabilized in ice-cold 100% methanol 
at 4˚C for 30 min. Following blocking with PBS containing 
0.1% Tween-20 (v/v) and 1% bovine serum albumin (w/v) 
(Sigma-Aldrich; Merck KGaA), the cells were incubated with a 
cleaved poly(ADP-ribose) polymerase 1 (PARP1) antibody (1:40; 
cat. no. 44-698G; eBioscience; Thermo Fisher Scientific, Inc.) 
overnight at 4˚C. Mouse IgG2b K isotype antibody (eBiosci-
ence; Thermo Fisher Scientific, Inc.) was used as a control. The 
samples were then washed by PBS twice and resuspended in 
PBS containing 2 mM EDTA and 5% FCS for flow cytometry.
For cell cycle analysis, the cells were fixed with 
70% ethanol for 15 min on ice, and stained with FxCycle™ 
PI/RNase staining solution (Thermo Fisher Scientific, Inc.) 
for 30 min. For apoptosis analysis, the cells were stained 
using an Annexin V Apoptosis Detection kit (eBioscience; 
Thermo Fisher Scientific, Inc.) following the manufacturer's 
instructions. Flow cytometry was performed using a Canto II 
flow cytometer (BD Bioscience, San Jose, CA, USA), and the 
data were analyzed using FCS Express version 4 Research 
Edition (De Novo Software, Glendale, CA, USA).
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Statistical analysis. The results are presented as data from three 
independent experiments and expressed as the mean ± stan-
dard deviation. The cumulative survival curves were generated 
using Kaplan-Meier plots and analyzed using log-rank test. 
Kruskal-Wallis test was used for comparisons of three or more 
groups followed by Tukey Honest Significant Difference as a 
post hoc test, and Mann-Whitney U test was used for compari-
sons between two groups. Statistical analysis was performed 
using SPSS v18 (SPSS, Inc., Chicago, IL, USA) and GraphPad 
Prism 6.0 (GraphPad Software, La Jolla, CA, USA). P<0.05 
was considered to indicate a statistically significant difference.
Results
Expression of psoriasin transcripts and its correlation with 
clinicopathological parameters in GC tissues. To determine the 
clinical relevance of psoriasin in GC progression, the transcript 
levels of psoriasin in GC (n=321) and the adjacent normal speci-
mens (n=173) were examined by RT-qPCR. As presented in in 
Table II, psoriasin was higher in GC tissues than in adjacent 
normal tissues (P<0.001), and a higher level of psoriasin was 
observed in advanced stages of GC (TNM III+IV) compared 
with early stages (TNM I+II; P<0.001; Table II). Notably, higher 
expression of psoriasin was detected in tumors with deeper 
infiltration (T3-4 vs. T1-2; P=0.011), lymph node involve-
ment (P<0.001) and distance metastasis (P<0.001, Table II). 
Furthermore, psoriasin exhibited higher expression in patients 
with GC that had died prior to the end of follow-up than in those 
who remained alive at the end of the follow-up period (P<0.001; 
Table II). Kaplan-Meier analysis and log-rank test revealed that 
patients with GC with higher expression of psoriasin had worse 
overall survival (P<0.001; Fig. 1A) and disease-free survival 
(P<0.001; Fig. 1B), compared with those with lower expression.
Psoriasin overexpression promotes cell proliferation, invasion 
and migration in AGS and HGC-27, and decreases adhesion 
in HGC-27 cells. AGS and HGC27 are two well-characterized 
gastric cancer cell lines (25,26). As demonstrated in Fig. 1, 
Figure 1. Survival curves of patients with GC, and the validation of psoriasin overexpression in GC cell lines. The high-low groups of patients were divided the 
median transcript values of psoriasin, guided by clinical stages (TNM staging). (A) Association between the transcript levels of psoriasin and overall survival. 
Low psoriasin group (median expression, 1), n=102; high psoriasin expression (median expression, 25), n=207, P<0.001. (B) The correlation between the 
transcript levels of psoriasin and disease-free survival. Low psoriasin group (median expression, 1), n=101; high psoriasin expression (median expression, 25), 
n=203. P<0.001. Reverse transcription-quantitative PCR analyzing mRNA expression of psoriasin in (C) AGS and (D) HGC-27 cell line, which was normal-
ized with the reference gene GAPDH. The data are presented as a ratio to pEF control. (E) Confirmation of psoriasin overexpression in AGS and HGC-27 
cells using conventional PCR. (F) Western blot analysis of the level of psoriasin expression in AGS and HGC-27 cell lines using an anti-S100A7/psoriasin 
antibody (clone 47C1068). *P<0.05, **P<0.01 vs. pEF control. PCR, polymerase chain reaction; pEF, cells transfected with the empty plasmid vector; PSOexp, 
cells transfected with psoriasin plasmid.
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the gene expression of psoriasin is low in these two GC cell 
lines, as indicated by RT-qPCR (Fig. 1C and D) and conven-
tional PCR (Fig. 1E). Western blotting also demonstrated 
that the protein levels of psoriasin in AGS and HGC27 were 
low (Fig. 1F). Attempts were made to subculture other GC 
cell lines, such as NUGC-1, MKN-45, MKN7 and MKN74. 
Unfortunately, they were either floating (NUGC-1, MKN-45) 
or was difficult expand during the establishment of the stable 
cells lines (MKN7 and MKN74). Therefore, AGS and HGC-27 
were to establish stable psoriasin-overexpressed cell lines 
(AGS PSOexp and HGC-27 PSOexp) to determine the role 
of psoriasin in the tumorigenesis and progression of GC. The 
mRNA and protein levels of psoriasin was markedly increased 
in AGS PSOexp and HGC-27 PSOexp cells compared with the 
cells that were transfected with the vector alone (AGS pEF and 
HGC-27 pEF) as verified by RT-qPCR (Fig. 1C and D), PCR 
(Fig. 1E) and western blotting (Fig. 1F).
There was a significant increase in cell proliferation in 
psoriasin-overexpressed cells compared with the controls, 
which was assessed by crystal violet assay (P<0.001; Fig. 2A 
Figure 2. Effect of psoriasin overexpression on the functions of AGS and HGC-27 cell lines in vitro. (A) Growth of cells that overexpress psoriasin (AGS PSOexp) 
compared with its control (AGS pEF). (B) Growth of cells that overexpress psoriasin (HGC-27 PSOexp) compared with its control (HGC-27 pEF). (C) Colony-
formation ability in AGS cells following psoriasin upregulation. (D) Increase in colony-formation ability in HGC-27 cell following psoriasin upregulation. 
Migration of (E) AGS and (F) HGC-27 cells determined by the ECIS system. Data are presents as resistance change (ohm). Higher values are proportional to 
higher levels of migration ability. *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001 vs. pEF. (G) Representative images of the invaded cells in chambers following 
incubation for 24 h and staining with calcein AM (right panel) and quantitative analysis of invasive cells (left panel). The density of green cells indicated the 
levels of invasion from different cell groups. (H) Representative images of adhesive cells after incubation on Matrigel for 1 h and stained with calcein AM 
(right) with corresponding quantitative analysis of adhesive cells (left). The density of green cells indicated the levels of adhesion from different cell groups. 
Data are presented as the mean ± standard deviation. pEF, cells transfected with the empty plasmid vector; PSOexp, cells transfected with psoriasin plasmid.
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and B). Similarly, cell colony formation was also enhanced in 
the psoriasin-overexpressed cells (Fig. 2C and D). However, 
there was no effect on the cell cycle profile following psoriasin 
overexpression (data not shown).
As psoriasin expression was positively associated with 
lymph node involvement and distant metastasis (Table II), the 
migratory and invasive abilities of GC cells were evaluated 
in vitro. The Matrigel invasion assay and ECIS assay demon-
strated that the overexpression of psoriasin dramatically 
enhanced migration (Fig. 2E and F) and invasion (Fig. 2G) in 
GC cell lines compared with the vector controls. Furthermore, 
upregulation of psoriasin significantly decreased cell-matrix 
adhesion in HGC-27 cells, but not in AGS cells (Fig. 2H). 
Together, these data suggest that psoriasin may function as an 
inducer of cell migration and invasion in GC.
Expression of epithelial-mesenchymal transition (EMT) 
markers in GC cells. Several EMT-associated molecules have 
been implicated in the development and progression of GC 
by altering the malignant properties of cancer cells (14,27). 
Therefore, the expression of epithelial markers, mesenchymal 
markers and EMT transcription factors were evaluated 
following overexpression of psoriasin by PCR and western 
blotting. The results demonstrated that the levels of N-cadherin 
and Snail expression were increased, while E-cadherin expres-
sion was decreased in AGS PSOexp and HGC-27 PSOexp 
cells compared with the empty vector controls. In addition, 
the upregulation of psoriasin promoted Slug and Zeb-1 expres-
sion levels in HGC-27 cells compared with the control cells, 
whereas the vimentin level was unchanged in both cell lines 
(Fig. 3A and B). Collectively, the activation of psoriasin may 
Figure 3. Effect of psoriasin overexpression on EMT and ERK expression in the gastric cancer cell lines, and effect of psoriasin on the motility and ERK 
expression in AGS cells that were treated with an ERK inhibitor. (A) Expression profiles of EMT in response to psoriasin overexpression in AGS and HGC-27 
cells as evaluated by PCR. (B) Expression profiles of EMT in response to psoriasin overexpression in AGS and HGC-27 cells as evaluated by western blotting. 
(C) Evaluation of ERK activity in AGS and HGC-27 cells by PCR. (D) Evaluation of ERK activity in AGS and HGC-27 cells by western blotting. Electric 
cell-substrate impedance sensing analysis demonstrating migration of (E) AGS pEF and (F) AGS PSOexp cells following treatment with 1 µM ERK inhibitor. 
Data are presented as the mean ± standard deviation. EMT, epithelial-mesenchymal transition; PCR, polymerase chain reaction; pEF, cells transfected with the 
empty plasmid vector; PSOexp, cells transfected with psoriasin plasmid; Zeb-1, zinc finger E-box-binding homeobox 1; ERK, extracellular signal-regulated 
kinase; p-, phospho-; DMSO, dimethyl sulfoxide.
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alter the patterns of EMT in GC cells, promoting cell invasion 
and migration.
Psoriasin enhances cell migration via activating ERK 
signaling in GC cells. The ERK signaling cascade is one of 
the key signaling pathways that regulates cell proliferation, 
invasion and migration by controlling multiple nuclear and 
cytoplasmic targets in cancer (28). In the present study, the 
effect of psoriasin on the ERK signaling pathway was inves-
tigated in GC. The upregulation of psoriasin significantly 
promoted the level of phosphorylated ERK (Tyr 204) protein, 
without altering the total ERK1/2 mRNA and protein levels 
in AGS and HGC-27 cells, compared with the control cells 
(Fig. 3C and D).
By contrast, there was no difference in the levels of 
cyclin D1 and cyclin D2 mRNA between the control cells and 
the cells that overexpressed psoriasin (Fig. 3C). Therefore, 
the effect of psoriasin on the viability of GC cells was 
unlikely due to the regulation of these regulatory proteins of 
cyclin-dependent kinases.
Treatment with an ATP-competitive ERK inhibitor 
suppressed the migratory ability of AGS cells (PSOexp cells 
and control cells), particularly in AGS PSOexp cells (Fig. 3E 
and F). Together, these results suggest that psoriasin may 
enhance cell migration at least partially via activation of ERK. 
Further study is required to determine whether ERK is a direct 
substrate of psoriasin.
Psoriasin overexpression increases resistance to cisplatin in 
GC cells. To determine the effect of psoriasin on cisplatin 
resistance in GC, the gene expression of psoriasin was 
analyzed in specimens from patients with GC that received 
pre-operative chemotherapy (n=87). The results indicated 
that levels of psoriasin expression were higher in patients 
that exhibited no response to neoadjuvant chemotherapy 
(P=0.023; Table III). Flow cytometry analysis of cleaved 
PARP was performed to evaluate the levels of apoptosis in the 
stable cell lines that were treated with cisplatin. As presented 
in Fig. 4A and B, in the presence of cisplatin, the less AGS 
PSOexp cells expressed cleaved PARP protein (8.95%) than 
the AGS pEF cells (16.87%), suggesting an increase in resis-
tance to cisplatin. However, such increase was not observed in 
HGC-27 cells, as the cleaved PARP expression was not mark-
edly altered between the HGC-27 PSOexp cell line (63.03%) 
and the HGC-27 pEF cell line (59.38%; Fig. 4A and B). The 
cell cycle analysis indicated that in response to the cisplatin 
treatment, a higher portion of AGS cells was arrested in the 
G2/M phase compared with PBS treatment in AGS pEF 
cells (58.68% vs. 22.51%) and AGS PSOexp cells (61.04% 
vs. 23.55%). However, there was no difference in cell cycle 
profile between the AGS PSOexp and AGS pEF cell lines in 
the presence of cisplatin. By contrast, the S-phase population 
of the HGC-27 PSOexp cells was increased compared with 
the pEF control cells in the presence of cisplatin (44.68% in 
HGC-27 pEF cells and 60.84% in HGC-27 PSOexp cells; 
Fig. 4C-F). Furthermore, psoriasin overexpression in AGS 
cells inhibited the cisplatin-induced increase in the levels of 
p53 and p21 proteins compared with the cells transfected with 
the backbone pEF plasmid (Fig. 4G and H). However, the cell 
viability assay showed that although psoriasin overexpression 
improved survival rates in the presence of particular doses of 
cisplatin (e.g. 6.25 µM) in transfected AGS and HGC-27 cells 
compared with the pEF controls (P<0.05), the overall dose-
dependent cytotoxic effect of cisplatin on the cell lines was 
similar to the control cell lines (data not shown). Therefore, 
the upregulation of psoriasin in GC cells may desensitize 
cells to cisplatin by promoting the proportion of cells in the 
S-phase or inhibiting apoptosis, instead of a direct effect via 
cellular cytotoxicity.
Discussion
Psoriasin is dysregulated in multiple solid tumors and 
performs multiple roles in a variety of pathophysiological 
processes, which are closely associated with tumorigenesis 
and cancer progression. However, knowledge on the 
Table III. Quantitative gene expression analysis of psoriasin in 
patients with gastric cancer receiving chemotherapy.
Variable n Psoriasin P-value
  expression
  (median)
Tissue   0.005
  Tumor 87 0.40
  Adjacent normal 83 1.09
Sex   0.816
  Male 63 0.41
  Female 24 0.33
Differentiation
  Differentiated 20 0.53
  Undifferentiated 59 0.41 0.500a
  Others   8 0.24 0.102a
Tumor size (mm)   0.202
  >50   9 0.41
  <50 78 0.29
Depth of invasion   0.116
  T1-2   9 0.19
  T3-4 78 0.41
Lymph node status   0.891
  Negative 16 0.34
  Positive 71 0.41
TNM staging   0.113
  I+II   9 0.34
  III+IV 78 0.48
Response to neoadjuvant
chemotherapy   0.023
  Response 30 0.24
  No response 57 0.50
aCompared with differentiated type; Mann-Whitney U test for 
comparisons between two groups; Kruskal-Wallis test for multiple 
group followed Tukey honest significant difference as post hoc test. 
TNM, tumor-node-metastasis.
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expression patterns and biological function of psoriasin in 
the progression of GC remains limited. In the present study, 
there was an increased level of psoriasin mRNA expression 
in GC tissues compared with adjacent normal tissues. 
Furthermore, this increase in psoriasin expression was also 
associated with lymph node involvement in patients, distant 
metastasis and advanced stages of the disease. These findings 
are consistent with the previous studies on cervical cancer 
and breast cancer (18,29). Additionally, Kaplan-Meier plot 
analysis indicated that higher psoriasin expression led to 
worse overall survival and disease-free survival, which was 
supported by the outcomes of meta-analysis from the Kaplan-
Meier Plotter (gastric cancer) database (http://kmplot.com/
analysis; data not shown). The association between psoriasin 
expression and clinicopathological characteristics indicates 
that psoriasin has a role in the development and progression 
of GC.
Figure 4. Effect of psoriasin overexpression on resistance to cisplatin in gastric cancer cells. (A) Flow cytometry analysis of the cleaved PARP levels in AGS 
and HGC-27 cells in response to treatment with 16.6 µM cisplatin for 24 h. Black line, isotype; red line, pEF cells; blue line, PSOexp cells. (B) Cell percentage 
in cleaved PARP protein production in AGS and HGC27 cell lines in treatment with cisplatin by flow cytometry. (C) Changes in AGS cells (pEF and PSOexp) 
cycle profile following treatment with 16.6 µM cisplatin for 24 h. (D) Changes in HGC-27 cells (pEF and PSOexp) cycle profile following treatment with 
16.6 µM cisplatin for 24 h. (E) Histogram of AGS cell cycle distribution. (F) Histogram of HGC-27 cell cycle distribution. (G) Levels of p21 and p53 proteins 
in AGS and HGC-27 cell lines that were treated with cisplatin as indicated by western blotting. (I) Fold change in p21 and p53 protein production in AGS 
cells in response to cisplatin as indicated by densitometric quantification of western blotting. The data from western blotting analysis were normalized using 
GAPDH. Data are presented as the mean ± standard deviation. *P<0.05 vs. relevant controls. PARP, poly(ADP-ribose) polymerase; pEF, cells transfected with 
the empty plasmid vector; PSOexp, cells transfected with psoriasin plasmid; PBS, phosphate-buffered saline.
Figure 5. Schematic illustration of the potential roles of psoriasin in gastric 
cancer cells. p-, phospho-; ERK, extracellular signal-regulated kinase; EMT, 
epithelial-mesenchymal transition.
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To further clarify the roles of psoriasin in gastric carcino-
genesis and progression, the effects of upregulating psoriasin 
on cell function were evaluated. In this study, overexpression 
of psoriasin in AGS and HGC-27 GC cell lines promoted cell 
proliferation, migration and invasion, and inhibited adhesion 
in the HGC-27 cell line. A recent study reported that psoriasin 
may promote cyclin activation and cell cycle progression in 
pancreatic cancer cells (30). However, in the present study 
psoriasin had no effect on cell cycle distribution and gene 
expression of cell cycle regulators.
EMT is a biological process that allows polarized epithe-
lial cells to undergo multiple changes in order to acquire a 
mesenchymal cell phenotype, therefore enhancing cell migra-
tion, invasion and metastasis (31). Loss of E-cadherin and 
increased expression of N-cadherin are hallmarks of EMT, 
which promote the interaction of the cell with endothelial 
and stromal components (27,32,33). Notably, the present 
data demonstrated that psoriasin drives the upregulation of 
N-cadherin, Snail, Slug and Zeb-1 expression and loss of 
E-cadherin expression in GC cells. Snail, Slug and Zeb-1, 
which are important transcription factors, trigger EMT by 
coordinating the induction of mesenchymal biomarkers and 
the repression of epithelial biomarkers (27). Collectively, these 
results suggest that psoriasin may be a potent inducer of EMT, 
which regulates cell invasion and migration in GC. However, 
the precise mechanism by which this occurs in GC requires 
further investigation.
ERK signaling, one of the most important intracellular 
pathways, has multiple functions in cancer cells, including roles 
in proliferation, cell cycle, EMT, migration, invasion, repres-
sion of apoptosis and induction of drug resistance (34-36). In 
the present study, migration was notably increased by ERK 
activation induced by psoriasin overexpression. Furthermore, 
the migration of AGS cells induced by psoriasin overexpres-
sion was inhibited by treatment with ERK inhibitor. Therefore, 
psoriasin may promote EMT by activating the ERK pathway, 
leading to enhanced migration and invasion of GC cells. 
However, the specific mechanism by which psoriasin affects 
cell migration and invasion requires further investigation.
Clinical data indicated that patients that positively 
responded to pre-operative chemotherapy had a significantly 
longer survival time than non-responders (5). Many studies 
have reported that the S100 proteins have the ability to regu-
late the sensitivity of tumor cells to chemotherapeutics (37-39). 
For instance, S100A11 sensitizes cells to cisplatin treatment 
in non-small cell lung cancer (40). However, to date, there has 
been no investigation into the association between psoriasin 
expression and chemotherapy resistance in tumors. To the best 
of our knowledge, the present study was the first to observe 
that elevated psoriasin expression in patients with GC was 
significantly associated with a poor pathological response to 
chemotherapy, suggesting that psoriasin might confer resis-
tance in GC to chemotherapeutic drugs. In vitro experiments 
demonstrated that cells with a higher level of psoriasin expres-
sion exhibited less sensitivity to cisplatin compared with the 
control cells. The molecular basis of resistance to chemo-
therapy is generally complex, involving multiple processes, 
including drug metabolism and transport, apoptosis and DNA 
repair (41). In order to investigate the underlying mechanism, 
the expression cleaved PARP was used as an indicator of 
apoptosis and the cell cycle following treatment of cells with 
cisplatin. Based on the results, psoriasin may inhibit the sensi-
tivity of GC cells to cisplatin by ameliorating cell apoptosis 
or inducing the S-phase arrest, depending on the molecular 
phenotype, epigenetic and genetic features or p53 status of the 
cells.
However, there were certain limitations of the present 
study. As AGS and HGC-27 cells were available, they were 
used to explore the effect of psoriasin overexpression in GC 
cells. It may be ideal to find a GC cell line that overexpresses 
S100A7 and possesses the phenotype of GC, and explore 
the further biological functions via psoriasin knockdown. In 
addition, as AGS and HGC27 cells have low tumor formation 
ability in mice, this study presented the role of psoriasin in 
GC cells via in vitro experiments only. In the future, another 
GC cell line should be used to determine the role of psoriasin 
in vivo.
In summary, to our best knowledge, this is the first 
report describing the role of psoriasin in GC and chemo-
therapy resistance in human tumors. Psoriasin expression is 
frequently increased in human GC cell lines and GC tissues, 
and its expression is associated with metastasis and a poor 
survival in patients with GC. Psoriasin overexpression in 
GC cells increased cell proliferation, migration and invasion. 
Furthermore, the promoting effects of psoriasin are potentially 
attributed to a positive effect on EMT-associated pathways via 
activation of ERK signaling (Fig. 5). As psoriasin overexpres-
sion leads to a higher tolerance to cisplatin in GC cells, patient 
with GC with a high level of psoriasin may be less sensitive 
to cisplatin. Therefore, the findings suggest that psoriasin has 
the potential as a therapeutic target in GC and may be a useful 
prognostic factor to predict the effectiveness of pre-operative 
chemotherapy in patients with GC.
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